Ampicillin Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Ampicillin Market is segmented By Indication (Infection (Intestine, Stomach, Bladder, and Others), Meningitis, Gonorrhea, Pneumonia, Others), By Dosage form (Oral Capsule, Oral Powder, Injectable Powder, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Ampicillin Market Size

The global ampicillin market size was valued US$ YY billion in 2022 and is estimated to reach US$ YY billion by 2031, growing at a high CAGR during the forecast period (2024-2031).  

Ampicillin is a penicillin antibiotic drug used to prevent or treat numerous infections such as intestines, stomach, meningitis, gonorrhea, pneumonia, bladder infections. Ampicillin is classified under the drug class Aminopenicillins.

Ampicillin Market Summary

For More Insights Request Free Sample

Ampicillin Market Dynamics

The ampicillin market growth is driven by the increasing incidence of infectious diseases such as pneumonia, gonorrhea, and syphilis are a major factor driving the global ampicillin market. Moreover, numerous contagious diseases, such as urinary tract infections, are rising across the globe. This is projected to fuel the demand for ampicillin antibiotics in the next few years. An increase in awareness campaigns by private and government organizations for controlling bacterial infectious diseases and a rise in investment in research and development activities are other factors that are anticipated to boost the global ampicillin market during the forecast period.

Increasing incidence of infectious diseases such as pneumonia, syphilis, is expected to drive the growth in the forecast period

The increasing incidence of pneumonia, syphilis is expected to drive market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, pneumococcal pneumonia causes around 150,000 hospitalizations every year, which surges the market progression in the U.S. Additionally, children, as well as the elderly, are at a higher risk of getting infected by pneumococcal disease, owing to the weak immune system. According to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year. Moreover, according to surveys conducted by the CDC, the United States, Syphilis saw an incidence increase of 13.3%, resulting in a total of 115,045 cases, and congenital syphilis experienced a spike of 40% from the previous year.

The antibiotic resistance in drugs coupled with the adverse effects of ampicillin is likely to hamper the market growth.

For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to beta-lactam. In addition, adverse reactions including hypersensitivity reactions, allergic reactions, anaphylaxis, and rashes associated with intake of ampicillin. Therefore, antibiotic resistance is expected to restrict the global ampicillin market.

COVID-19 Impact Analysis

The whole world is presently struggling with the COVID-19 pandemic. This infection leads to pneumonia, severe and acute respiratory disorders, multiple organ failure, and in severe cases, death. The geriatric population is more prone to COVID-19. The secondary bacterial infection caused due to COVID-19 can be treated by ampicillin. This is likely to drive the ampicillin market.

Governments of developing countries are making significant investments to modernize healthcare infrastructure in their respective countries, which is likely to increase access to healthcare. This is expected to increase the demand for global ampicillin drugs.

Ampicillin Market Segmentation Analysis

The oral segment is expected to hold largest share in this market segment

The oral segment is expected to hold a dominant position in the ampicillin market as their variable penetration to different target sites of infection, drug solubility, and extent of protein binding determine the strong effectiveness. The oral route of administration of ampicillin is possible because Aminopenicillins are not deactivated by acid hydrolysis, however, they are susceptible to hydrolysis by beta-lactamase and hence, sometimes beta-lactamase inhibitors are administered. Aminopenicillins are also effective against several infections caused by gram-negative as well as gram-positive bacteria such as H. influenza, and E. coli.

The infections segment is expected to hold largest share in this market segment

Increasing cases of infections are expected to stock the overall growth of the ampicillin market. Changing lifestyles and practicing unhealthy lifestyles, and lack of cleanliness are increasing the number of bacterial infections. According to Centres for Disease Control and Prevention, approximately 11,000 to 24,000 invasive bacterial infections occur each year in the United States. Each year between 1,200 and 1,900 people die due to invasive group A strep disease. The overall prevalence of intestinal infections was 56.9%. Bladder infections are common, especially among women. According to the National Institute of Health, research suggests that at least 40 to 60 percent of women develop a UTI during their lifetime, and most of these infections are bladder infections. One in 4 women is likely to have a repeat infection.

The retail pharmacies segment is expected to hold largest share in this market segment

The retail Pharmacies segment is expected to dominate during the forecast period. Ampicillin medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost ampicillin market growth.

Global Ampicillin Market Geographical Share

North America region holds the largest market share of global ampicillin market

North America is projected to account for a dominant share of the global ampicillin market. This is attributed to an increase in sexually transmitted diseases such as gonorrhea and syphilis in the U.S. According to CDC, the country reported 555,608 cases of gonorrhea in 2017, accounting for 171.9 cases per 100,000 population and an increase of 67% since 2013. The presence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel therapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities.

Ampicillin Market Companies and Competitive Landscape

The global ampicillin market is highly competitive with presence of global companies.  Some of the key players which are contributing to the growth of the market include ACS Dobfar S.p.A, Thermo Fisher Scientific Inc, Viatris Inc, Sanofi, Indian Drugs & Pharmaceuticals Ltd, Jagsonpal Pharmaceuticals Limited, Zydus Cadila, Pharmed Medicare P. Ltd, Lyka Hetro Labs, Hetero Healthcare Limited, career henan chemical co, Xiamen AmoyChem Co., Ltd, HubeiwidelychemicaltechnologyCo., Ltd, CONIER CHEM AND PHARMA LIMITED, SIMAGCHEM CORP. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Ampicillin Market Key Companies to Watch

Viatris Inc

Overview: Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn on November 16, 2020. It operates approximately 50 manufacturing sites, 45000 employees which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Product Portfolio: Its portfolio comprises molecules across a range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally-recognized brands, generic, complex generic and branded medicines, a portfolio of biosimilars, and a variety of over-the-counter consumer products.

Key Developments: In Nov 2020, Viatris Inc. launched following the successful combination of Mylan N.V. and Pfizer's Upjohn business. By combining these two complementary legacy companies, Viatris has the scientific, manufacturing and distribution expertise with proven regulatory, medical and global commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.

Why Purchase the Report?

• Visualize the composition of the ampicillin market segmentation by indication, by dosage form and by distribution channel highlighting the key commercial assets and players.
• Identify commercial opportunities in ampicillin market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of ampicillin market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global ampicillin market report would provide an access to an approx. 61 market data table, 55 figures and 200 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers